Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy

Ian S. Hagemann, Catherine E. Cottrell, Christina M. Lockwood

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations


In cancer medicine, next generation sequencing (NGS) has emerged as a practical method to generate patient- and tumor-specific genetic data for optimal selection of targeted therapies. Targeted sequencing allows clinical testing to focus on cancer-related genes, thus maximizing the test's sensitivity and specificity for actionable variants. In this review, we summarize the current regulatory environment surrounding clinical NGS, including regulations and professional opinions established by the College of American Pathologists, the Centers for Disease Control and Prevention, the Clinical Laboratory Improvement Amendments, the Clinical and Laboratory Standards Institute, the Association for Molecular Pathology, the New York State Department of Health, and the American College of Medical Genetics. We outline practical considerations for the design of targeted NGS assays, with an emphasis on capture-based methods. Finally, we discuss components of the validation process for clinical NGS assays as well as challenges that still remain for clinical NGS.

Original languageEnglish
Pages (from-to)420-431
Number of pages12
JournalCancer Genetics
Issue number12
StatePublished - Dec 1 2013


  • Laboratory standards
  • Massively parallel sequencing
  • Regulatory compliance
  • Validation studies

Fingerprint Dive into the research topics of 'Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy'. Together they form a unique fingerprint.

Cite this